#news #biotech Alnylam eyes quickie givosiran filing after hitting interim goal

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Alnylam eyes quickie givosiran filing after hitting interim goal .Alnylam is set to file for accelerated FDA approval of givosiran on the strength of interim data from a phase 3 trial. The readout linked the ALAS1-targeted RNAi to a statistically-significant drop in urinary aminolevulinic acid, a biomarker Alnylam and the FDA think may predict clinical benefit. 

from FierceBiotech: Biotech https://ift.tt/2DzAzlZ